ストックスクリーナーアプリを入手
25.84
0.35%
-0.09
アフターアワーズ：
25.84
前日終値:
$25.93
開ける：
$25.93
24時間の取引高:
595.41K
Relative Volume:
0.65
時価総額：
$1.20B
収益：
$681.75M
当期純損益:
$70.47M
株価収益率:
17.82
EPS:
1.45
ネットキャッシュフロー:
$173.19M
1週間 パフォーマンス:
+0.35%
1か月 パフォーマンス:
-4.30%
6か月 パフォーマンス:
+52.81%
1年 パフォーマンス:
-15.17%
1日の値動き範囲:
$25.36
$25.99
1週間の範囲:
$25.33
$26.44
52週間の値動き範囲:
$11.16
$31.64
Pacira Biosciences Inc Stock (PCRX) Company Profile
名前
Pacira Biosciences Inc
セクター
電話
650-242-8052
住所
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
PCRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
25.84 | 1.19B | 681.75M | 70.47M | 173.19M | 1.45 |
|
HLN
Haleon Plc Adr
|
11.35 | 50.14B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
168.63 | 72.38B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.79 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 45.51B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.45B | 16.54B | -1.64B | 749.00M | -1.45 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-30 | アップグレード | Truist | Sell → Hold |
| 2024-08-13 | ダウングレード | Truist | Buy → Sell |
| 2024-08-12 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2024-08-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-03-07 | 再開されました | JP Morgan | Overweight |
| 2023-12-20 | 開始されました | Raymond James | Outperform |
| 2023-08-03 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | 再開されました | Wedbush | Outperform |
| 2022-10-21 | 再開されました | Jefferies | Buy |
| 2022-01-03 | 再開されました | JP Morgan | Overweight |
| 2021-07-26 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-04-21 | 再開されました | JP Morgan | Neutral |
| 2021-04-09 | 開始されました | Berenberg | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2021-02-11 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | 繰り返されました | Needham | Buy |
| 2020-05-27 | 開始されました | Guggenheim | Neutral |
| 2020-04-07 | 開始されました | Northland Capital | Outperform |
| 2020-03-20 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-24 | 開始されました | SunTrust | Buy |
| 2020-01-23 | 開始されました | SunTrust | Buy |
| 2019-11-06 | 開始されました | BTIG Research | Buy |
| 2019-06-11 | 開始されました | Barclays | Overweight |
| 2019-05-06 | アップグレード | Mizuho | Underperform → Neutral |
| 2019-05-02 | アップグレード | Stifel | Sell → Hold |
| 2019-02-01 | ダウングレード | Mizuho | Neutral → Underperform |
| 2018-08-06 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-03-21 | 繰り返されました | Mizuho | Neutral |
| 2018-02-16 | ダウングレード | Needham | Buy → Hold |
| 2018-01-19 | 開始されました | Seaport Global Securities | Buy |
| 2018-01-04 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-01-03 | 開始されました | Leerink Partners | Mkt Perform |
すべてを表示
Pacira Biosciences Inc (PCRX) 最新ニュース
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by ProShare Advisors LLC - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences’s First Quarter 2025 Misses Estimates - Orthopedics This Week
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by Nuveen Asset Management LLC - Defense World
Grabar Law Office Investigates Claims on Behalf of - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out - ACCESS Newswire
Trading (PCRX) With Integrated Risk Controls - news.stocktradersdaily.com
Ameriprise Financial Inc. Acquires 194,597 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Pacira BioSciences (NASDAQ:PCRX) adds US$78m to market cap in the past 7 days, though investors from three years ago are still down 57% - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2025-05-18 | Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation | Press Release - Stockhouse
The Manufacturers Life Insurance Company Sells 458 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Comerica Bank - Defense World
Northern Trust Corp Buys 145,205 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit - GuruFocus
Pacira (PCRX) Reports Promising Data on PCRX-201 Gene Therapy fo - GuruFocus
Pacira (PCRX) Reports Promising Data on PCRX-201 Gene Therapy for Knee Osteoarthritis | PCRX Stock News - GuruFocus
Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee - The Manila Times
Pacira BioSciences Presents New Data on the Effects of - GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences - GlobeNewswire
Pacira Biosciences announces $300M share repurchase program - MSN
(PCRX) Trading Report - news.stocktradersdaily.com
Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation - PR Newswire
2025-05-13 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Reach Out | Press Release - Stockhouse
Raymond James Financial Inc. Invests $190,000 in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Tower Research Capital LLC TRC - Defense World
Needham & Company LLC Cuts Pacira BioSciences (NASDAQ:PCRX) Price Target to $30.00 - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Shareholders of Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your RightsPCRX - ACCESS Newswire
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Down on Analyst Downgrade - Defense World
Pacira BioSciences (PCRX) Stock Rating Maintained but Price Targ - GuruFocus
Levi & Korsinsky Reminds Pacira BioSciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025PCRX - ACCESS Newswire
Pacira outlines growth potential with $725M-$765M 2025 revenue target and EXPAREL expansion to 2039 - MSN
Earnings call transcript: Pacira Q1 2025 shows revenue miss, stock dips - Investing.com Australia
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates - Nasdaq
Pacira BioSciences (PCRX) Stock Rating Maintained but Price Target Lowered | PCRX Stock News - GuruFocus
Where Pacira BioSciences Stands With Analysts - Benzinga
Pacira BioSciences Q1 2025 Earnings Call Transcript - MarketBeat
Pacira Q1 Adjusted Earnings Unchanged; Revenue Rises; 2025 Sales Guidance Steady - marketscreener.com
Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call Highlights: Strong EXPAREL Sales and ... - Yahoo Finance
Decoding Pacira BioSciences Inc (PCRX): A Strategic SWOT Insight - GuruFocus
Pacira BioSciences Reports Q1 2025 Financial Results - TipRanks
Pacer Advisors, Inc. Significantly Reduces Holdings in Pacira Bi - GuruFocus
Pacer Advisors, Inc. Reduces Stake in Pacira BioSciences Inc - GuruFocus
Pacira BioSciences Reports First Quarter 2025 Financial Results - GlobeNewswire
Pacira (PCRX) Q1 Earnings Surpass Estimates - Nasdaq
Pacira BioSciences Inc Q1 2025 Earnings: EPS of $0.10 Misses Estimate, Revenue at $168.9 Million Below Forecast - GuruFocus
PACIRA BIOSCIENCES Earnings Results: $PCRX Reports Quarterly Earnings - Nasdaq
Pacira Biosciences Inc (PCRX) 財務データ
収益
当期純利益
現金流量
EPS
18.36%
0.52%
大文字化:
|
ボリューム (24 時間):